2023, Vol. 3, Issue 1, Part B
Formulation and design optimization of repaglinide loaded transferosomes for management of type II diabetes mellitus
Author(s): Sai Sambit Nayak and Rajendra K Jangde
Abstract: Background: An anti-diabetic drug called Repaglinide is used to treat type II diabetes. Repaglinide, a lipophilic medication with a short (1 h) half-life and little solubility in water is classified as a class II biopharmaceutical chemical (BCS) chemical. Only around 55% of drugs with a high metabolism in the first pass are bioavailable orally.Objective: The development of repaglinide-loaded transferosomes was the key objective of the current study in order to boost transdermal bioavailability.Method: Thin Film Hydration technique was used to create the transferosomes. Results: SEM examination revealed that the majority of the transfersomes containing repaglinide had spherical forms. Deformable vesicle formulations were found to have an entrapment efficacy of 68.8% to 87.41%. The F9 formulation has high entrapment efficiency (maximum 87.41%). Transfersomes were discovered to improve the release, according to studies on in vitro release. Stability tests for transferosomes were carried out over a three-month period to look at how various levels of temperature affected the total amount of medication entrapped and destroyed, the uniformity of the content, and the physical appearance.Conclusions: Finally, it may be inferred from the available data that transferosomes were a viable option for transdermal distribution, to extend the release and to enhance site specificity of the medication repaglinide.
DOI: 10.22271/27889262.2023.v3.i1b.76
Pages: 115-125 | Views: 659 | Downloads: 376
Download Full Article: Click Here
How to cite this article:
Sai Sambit Nayak, Rajendra K Jangde. Formulation and design optimization of repaglinide loaded transferosomes for management of type II diabetes mellitus. Nat J Pharm Sci 2023;3(1):115-125. DOI: 10.22271/27889262.2023.v3.i1b.76
